Related Experiment Video
Updated: May 28, 2026
07:36
Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
Published on: September 26, 2018
Targeting the aldosterone pathway in cardiovascular disease
Finn Gustafsson1, Michel Azizi, Johann Bauersachs
1Department of Cardiology, Rigshospitalet, Copenhagen, Denmark. finng@dadlnet.dk
Fundamental & Clinical Pharmacology
|November 3, 2011
Summary
Aldosterone significantly contributes to cardiovascular disease. Targeting the aldosterone pathway offers therapeutic benefits, including reduced blood pressure and improved patient outcomes in heart conditions.
Area of Science:
- Endocrinology
- Cardiology
- Pharmacology
Background:
- Aldosterone is implicated in cardiovascular disease pathogenesis.
- Clinical trials show aldosterone pathway intervention improves outcomes in heart failure and myocardial infarction.
- Recent research explores aldosterone's cellular roles in cardiovascular disease.
Purpose of the Study:
- To review recent advancements in understanding aldosterone's role in cardiovascular disease.
- To highlight potential intervention targets and mechanisms.
- To discuss ongoing and future clinical trials.
Main Methods:
- Literature review of recent developments.
- Synthesis of findings from basic science and clinical trials.
- Discussion of ongoing clinical trials.
Main Results:
- Aldosterone pathway intervention reduces blood pressure and albuminuria.
- The relative roles of glucocorticoids and aldosterone in mineralocorticoid receptor activation are under investigation.
- Optimal aldosterone modulators, treatment timing, and patient populations are active research areas.
Conclusions:
- Aldosterone is a critical factor in cardiovascular disease.
- Targeting the aldosterone pathway presents therapeutic opportunities.
- Further research and clinical trials are needed to optimize interventions.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...